06887 东阳光药 通函：致登记股东之通知信函及回条 – 以电子方式发布公司通讯之安排
SUNSHINE LAKE PHARMA CO., LTD.
广东阳光药业股份有限公司
(A joint stock company incorporated in the People’s Republic of China with limited liability)
（于中华人民共和国注册成立的股份有限公司）
(Stock Code股份代号: 6887)
18 August 2025
Dear registered shareholder(s),
Arangement of Electronic Disemination of Corporate Comunications
Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) under the expansion of paperles listing regime
and electronic disemination of corporate comunications that came into efect on 31 December 2023, Sunshine Lake Pharma Co., Ltd. (the “Company”) is writing to inform you that the Company has adopted electronic
disemination of corporate comunications (the “Corporate Comunications”), which mean any documents isued or to be isued by the Company for the information or action of holders of any of its securities,
including but not limited to (a) the directors’ report, its anual acounts together with a copy of the auditors’ report and, where aplicable, its sumary financial report; (b) the interim report and, where aplicable, its
sumary interim report; (c) a notice of meting; (d) a listing document; (e) a circular; and (f) a proxy form.
Please note that both the English and Chinese versions of al future Corporate Comunications wil be available electronicaly on the websites of the Company at w.hecpharm.com and the Stock Exchange at
w.hkexnews.hk in place of printed copies.
Solicitation of electronic contact details
To ensure timely receipt of the Actionable Corporate Comunications
(Note)
, the Company recomends you provide your email adres by scaning your personalized QR code printed on the enclosed reply form (the
“Reply Form”). Alternatively, you may sign and return the Reply Form to the Company’s Hong Kong share registrar (the “Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Flor,
Hopewel Centre, 183 Quen’s Road East, Wan Chai, Hong Kong.
If the Company does not receive a functional email adres in your reply, until such time that the functional email adres is provided to the Share Registrar, the Company wil send the Actionable Corporate
Comunications in printed form in the future.
If you want to receive the Corporate Comunications in printed form, please complete and return the Reply Form on the reverse side herein to the Share Registrar or send an email to hecpharmaIR@hec.cn specifying
your name, adres and request to receive the Corporate Comunications in printed form. Please note that such instruction shal be valid for one year unles being revoked or superseded (whichever is earlier) starting
from the receipt date of your instruction and wil expire thereafter.
Should you have any queries relating to this leter, please contact the Company at +86-769-88615888-2051 during busines hours from 9:00 a.m. to 12:00 p.m. and from 2:00 p.m. to 5:00p.m. (Hong Kong time), Monday
to Friday, excluding public holidays in Hong Kong and Mainland China.
Note: Actionable Corporate Comunications refer to any corporate comunication that seks instructions from an isuer’s securities holders on how they wish to exercise their rights or make an election as the isuer’s
securities holders.
各位登记股东：
以电子方式发布公司通讯之安排
根据自2023年12月31日起生效的扩大无纸化上市机制及以电子方式发布公司通讯规定下香港联合交易所有限公司（「联交所」）证券上市规则（「上市规则」）第2.07A条，广东阳光药业股份有
限公司（「公司」）谨此通知 阁下，公司已采用以电子方式发布公司通讯（「公司通讯」）之安排，该公司通讯是指公司为向其任何证券持有人提供资讯或提醒其采取行动而发布或将要发布的任何
文件，包括但不限于(a) 董事报告、年度帐目以及审计报告副本以及（如适用）财务摘要报告； (b) 中期报告及其中期报告摘要（如适用）； (c) 会议通知； (d) 上市文件； (e) 通函；和 (f) 委任表
格。
请注意，所有未来公司通讯的英文版和中文版将在公司网站w.hecpharm.com和联交所网站w.hkexnews.hk上提供，以代替印刷本。
征集电子联络资料
为确保及时收到可供采取行动的公司通讯
（附注）
，公司建议 阁下透过扫描本函背页之回条（「回条」）上列印的 阁下专属二维码来提供 阁下的电子邮件地址。或者， 阁下也可以签署回条并交回
公司的香港股份过户登记处（「股份过户处」）香港中央证券登记有限公司，地址为香港湾仔皇后大道东183号合和中心17M楼。
如果公司没有收到 阁下的有效电子邮件地址，直至股份过户处收到 阁下有效的电子邮件地址前，本公司未来将以印刷本形式发送可供采取行动的公司通讯。
若 阁下希望收取公司通讯之印刷版，请填妥本函背页之回条并交回股份过户处，或发送电子邮件至hecpharmaIR@hec.cn，并注明 阁下的姓名、地址以及收取公司通讯印刷版的要求。请注意，收取
未来公司通讯印刷版之指示由收悉 阁下指示当日起计一年内有效，除非被撤销或取代（以较早者为准），此后将过期。
如 阁下对本函件有任何疑问，请于办公时间星期一至五（香港及中国大陆公众假期除外）上午9时正至12时正以及下午2时正至5时正（香港时间）期间致电+86-769-88615888-2051联络公司查询。
2025年8月18日
附注：可供采取行动的公司通讯指任何涉及要求发行人的证券持有人指示其拟如何行使其有关证券持有人的权利或作出选择的公司通讯。
Yours faithfuly
On behalf of the Board
Sunshine Lake Pharma Co., Ltd.
ZHANG Yingjun
Chairman
代表董事会
广东阳光药业股份有限公司
董事长
张英俊
谨启
Please cut the mailing label and stick it on an envelope to return this form to us.
No postage is necesary if posted in Hong Kong.
当 阁下寄回此回条时，请将邮寄标签剪贴于信封上。
如在本港投寄， 阁下无需支付邮费或贴上邮票。
CS3049 SLPH
REPLY FORM 回条
To: Computershare Hong Kong Investor Services Limited (the “Share Registrar”) 致： 香港中央证券登记有限公司 （「股份过户处」）
17M Flor, Hopewel Centre 香港湾仔皇后大道东183号
183 Quen’s Road East, Wanchai, Hong Kong 合和中心17M楼
(Please chose ONLY ONE of the options below)
(请从以下选项中只选择其中一项)
Option 1: Provide your email adres for receipt of future Actionable Corporate
Comunications
(Note 3)
of the Company via electronic disemination by scaning
your personalized QR code
选项1： 扫描 阁下专属二维码提供 阁下之电子邮件地址，以接收公司未来通过电子方
式发布可供采取行动的公司通讯
(附注3)
You are NOT required to return this Reply Form if you chose “Option 1”.
如选择了「选项1」， 阁下无须交回本回条。
Personalized QR Code
专属二维码
Option 3: I/we hereby request for receipt of Corporate Comunications* in printed form (Please mark “✓” in the below box if aplicable)
选项3： 本人/吾等现要求收取公司通讯
*
印刷版 （如适用，请在以下方格内划上「✓」号）
receive future Corporate Comunications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction.
(Note 5)
收取未来公司通讯
*
的印刷本，并已知悉本指示由收取指示日期起计一年内有效。
(附注5)
Printed English version 英文印刷本 Printed Chinese version 中文印刷本 Printed English and Chinese versions 中文及英文印刷本
Signature(s):
(Note 1)
签名：
(附注1)
Contact number:
联络电话号码：
Date:
日期：
Notes 附注：
1. Please complete al your details clearly. If your shares are held in joint names, al of the joint shareholders should jointly sign this Reply Form in order to be valid.
请清楚填妥 阁下之所有资料。如属联名股东，则本回条须由所有联名股东联合签署，方为有效。
2. Any Reply Form with no signature or otherwise incorectly completed wil be void.
任何回条若未有签署或在其他方面填写不正确，则将会作废。
3. If the Company does not receive a functional email adres in your reply, you wil be unable to receive notifications regarding the publication of Corporate Comunications*. Actionable Corporate Comunications refer to any corporate comunication that seks instructions from isuer’s securities holders
on how they wish to exercise their rights or make an election as the isuer’s securities holder.
如公司没有收到 阁下的有效电子邮件地址， 阁下将无法收到有关发布公司通讯*的通知。可供采取行动的公司通讯指任何涉及要求发行人的证券持有人指示其拟如何行使其有关证券持有人的权利或作出选择的公司通讯。
4. If you provide more than one email adres by QR code, email, reply form and/or other means, only the latest one email adres provided wil be registered.
如 阁下通过二维码、电邮、回条及/或其他方式提供多于一个的电子邮件地址，只有 阁下最后提供的电子邮件地址将会被用于登记。
5. If you mark “✓” in the box in Option 3, no email adres wil be registered and only Corporate Comunications* in printed form wil be received.
如 阁下在选项3方格内划上「✓」号，将不会有电子邮件地址被登记，只有公司通讯*的印刷版会被收取。
6. For the avoidance of doubt, the Company does not acept any other instructions given on this Reply Form.
为免存疑，在本回条上的任何额外指示，公司将不予处理。
- , Corporate Comunications refer to any documents isued or to be isued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its anual acounts together with a copy of the auditors’ report and, where
aplicable, its sumary financial report; (b) the interim report and, where aplicable, its sumary interim report; (c) a notice of meting; (d) a listing document; (e) a circular ;and (f) a proxy form.
除非另有注明，公司通讯乃指公司已发出或将予发出以供其任何证券的持有人参照或采取行动的任何文件，其中包括但不限于(a) 董事报告、年度帐目以及审计报告副本以及财务摘要报告（如适用）； (b) 中期报告其中期报告摘要（如适用）； (c) 会议通知； (d) 上市文件； (e) 通函；和 (f) 委任表格。
PERSONAL INFORMATION COLECTION STATEMENT
收集个人资料声明
(i) “Personal Data” in this statement has the same meaning as “personal data” in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong (the “PDPO”).
本声明中所指的「个人资料」与香港法例第486章《个人资料（私隐）条例》（「《私隐条例》」）中「个人资料」的涵义相同。
(i) Your Personal Data provided in this Reply Form wil be used in conection with, including but not limited to, the Company’s electronic disemination of Corporate Comunications* and to liaise with you on other maters relating to your holdings in the Company. Your suply of Personal Data to the Company is
on a voluntary basis. In case of a failure to provide suficient information, the Company may not be able to proces your instruction and/or request as stated in this Reply Form.
阁下于本回条所提供的个人资料将用于(包括但不限于)有关公司以电子方式发布公司通讯*及就 阁下持有的公司证券有关的其他事宜上与 阁下联络。 阁下是自愿向本公司提供个人资料。若 阁下未能提供足够资料，本公司可能无法处理 阁下在本回条上所述的指示及/或要求。
(i) Your Personal Data may be disclosed or transfered by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and wil be retained for such period as may be necesary for our verification and record purposes.
公司可就任何所说明的用途或在法例规定的情况下，将 阁下的个人资料披露或转移给公司的附属公司、股份过户处、及/或其他公司或团体，并将在适当期间保留该等个人资料作核实及纪录用途。
(iv) You have the right to request aces to and/or corection of your Personal Data in acordance with the provisions of the PDPO. Any such request for aces to and/or corection of your Personal Data should be in writing, by mail to the Hong Kong Privacy Oficer of the Share Registrar
at 17M Flor, Hopewel Centre, 183 Quen’s Road East, Wanchai, Hong Kong or by email at PrivacyOficer@computershare.com.hk.
阁下有权根据《私隐条例》的条文查阅及/或修改 阁下的个人资料。任何该等查阅及/或修改个人资料的要求均须以书面方式邮寄至股份过户处（地址为香港湾仔皇后大道东183号合和中心17M楼）向香港隐私主任提出，或发送电邮至PrivacyOficer@computershare.com.hk。
Option 2: I/we hereby provide my/our email adres in writing for receipt of future Actionable Corporate Comunications
(Note 3)
of the folowing listed
company (the “Company”) via electronic disemination
选项2： 本人/吾等现以书面提供本人/吾等之电子邮件地址，以确保收到以下上市公司（「公司」）未来通过电子方式发布的可供采取行动的公司通讯
(附注3)
Name of Securities holder(s) 证券持有人姓名 : Name of the listed company 上市公司名称 :
SUNSHINE LAKE PHARMA CO., LTD.
广东阳光药业股份有限公司
Email adres电邮地址:
(Note 3 / 附注3)
Mailing Label 邮寄标签
Computershare Hong Kong Investor Services
Frepost No.
Hong Kong